Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of intravenous HY-001 versus colistimethate sodium for complicated urinary tract infection or acute pyelonephritis at risk for multidrug-resistant Gram-negative infection
2019-000910-12Phase 2Completed
- Sponsor
- Helperby Therapeutics
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of colistimethate sodium in complicated urinary tract infection (cUTI) and acute pyelonephritis (2 arms), sponsored by Helperby Therapeutics. Primary endpoint: Primary composite efficacy endpoint. Started Mar 2020; status: completed.
02
Drugs
colistimethate sodium
03
Conditions
complicated urinary tract infection (cUTI)acute pyelonephritis
Beyond the preview
Go deeper on 2019-000910-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000910-12.